ATI RN
Chapter 14 Drugs for the Reproductive System Questions
Question 1 of 5
For the treatment of hypogonadism and impotence, testosterone/dihydrotestosterone can be administered by the following route/routes:
Correct Answer: D
Rationale: The correct answer is D because testosterone and dihydrotestosterone are typically administered through intramuscular or transdermal routes. Intramuscular injection ensures direct delivery into the bloodstream, while transdermal patches allow for gradual absorption through the skin. Oral administration is not preferred due to liver metabolism. Therefore, options A and C alone are not sufficient. The combination of both intramuscular (B) and transdermal (C) routes provides effective and reliable delivery for treating hypogonadism and impotence.
Question 2 of 5
The following drug has potent antiandrogenic and weak progestational activity:
Correct Answer: C
Rationale: The correct answer is C: Cyproterone acetate. Cyproterone acetate is a potent antiandrogen due to its ability to competitively block androgen receptors. It also exhibits weak progestational activity, making it effective in treating conditions like hirsutism and acne. Ethylestrenol (A) is an anabolic steroid, Clomiphene citrate (B) is a selective estrogen receptor modulator, and Magestrol acetate (D) is a progestin with no antiandrogenic properties.
Question 3 of 5
Finasteride acts by:
Correct Answer: D
Rationale: The correct answer is D because finasteride inhibits the enzyme 5-alpha reductase, which is responsible for converting testosterone to dihydrotestosterone (DHT). By lowering circulating as well as prostatic DHT concentration, finasteride effectively reduces the androgenic effect on the prostate, leading to shrinkage of the prostate gland and improvement in symptoms of benign prostatic hyperplasia. A: Blocking testosterone receptors in the prostate gland is incorrect because finasteride does not directly block testosterone receptors. B: Reducing testosterone secretion from testes is incorrect because finasteride does not affect testosterone secretion. C: Reducing LH secretion from pituitary is incorrect because finasteride does not directly influence LH secretion.
Question 4 of 5
Transdermal estradiol differs from oral estrogen therapy in that it:
Correct Answer: D
Rationale: Failed to generate a rationale of 500+ characters after 5 retries.
Question 5 of 5
The estrogen commonly used for hormone replacement therapy in menopausal women is:
Correct Answer: D
Rationale: The correct answer is D: Conjugated estrogens. Conjugated estrogens are derived from the urine of pregnant mares and contain a mixture of estrogens like estrone and equilin. They are commonly used for hormone replacement therapy in menopausal women due to their effectiveness in relieving menopausal symptoms. A: Ethinylestradiol is a synthetic estrogen commonly used in birth control pills, not as hormone replacement therapy in menopausal women. B: Estradiol benzoate is a form of estradiol used in veterinary medicine, not typically used in hormone replacement therapy for menopausal women. C: Diethylstilbestrol is a synthetic nonsteroidal estrogen that has been largely discontinued due to its association with serious health risks, not commonly used for hormone replacement therapy in menopausal women.